Skip to NavigationSkip to content

trial failure

Anthera pulls the plug on Sollpura after Phase 3 failure, shares plummet 84%

Anthera Pharmaceuticals has announced that it is to terminate development of its investigational pancreatic enzyme replacement therapy (PERT) Sollpura after it failed to meet its primary endpoint in the treatment of exocrine pancreatic insufficiency due to cystic fibrosis.

VBL Therapeutics' shares plummet on Phase 3 glioblastoma failure

Israeli drug development firm VBL Therapeutics has been left reeling after it announced that its lead oncology product ofranergene obadenovec, or VB-111, had failed to meet its primary endpoint in a Phase 3 study investigating its efficacy when used in combination with Roche’s Avastin (bevacizumab), as opposed to Avastin alone, in the treatment of recurrent glioblastoma (rGBM).

Dermira terminates acne drug after Phase 3 failure, wiping $667m from market value

Skin specialist biopharma firm Dermira has seen its stock crash and burn following the announcement that it plans to terminate development of acne treatment olumacostat glasaretil after it failed to show statistically significant efficacy as a therapy for moderate to severe forms of the skin condition in patients older than nine years old.

Biogen halts Tysabri trial after failure in acute ischemic stroke

Biogen has halted its investigation into the efficacy of its humanised monoclonal antibody Tysabri (natalizumab) in the treatment of acute ischemic stroke (AIS) after it failed to meet its primary and secondary endpoints in a Phase 2b trial, demonstrating no improvement over placebo.

FDA halts Bellicum trial over brain disease in participants, shares crash 48%

Image Credit: Bellicum Pharmaceuticals

Texas-based clinical-stage company Bellicum Pharmaceuticals has taken a massive stock hit after the FDA put a hold on its trials of its T-cell therapy BPX-501 due to three cases of encephalopathy in participants that are thought to be treatment-related.

Galectin Therapeutics' share value plummets by half after NASH drug failure

Galectin Therapeutics has seen its share value almost halve after its revealed that GR-MD-02, its experimental treatment for non-alcoholic steatohepatitis (NASH) cirrhosis, had missed its primary endpoint in a Phase 2b trial.

Stem cell therapy fails to improve symptoms of peripheral artery disease

A new study has revealed that a promising stem cell therapy failed to improve ability to walk in patients with peripheral artery disease (PAD), a condition that causes pain or weakness in the legs due to atherosclerotic blockages in the legs.

Amicus pulls plug on rare skin disease drug after Phase 3 failure

New Jersey-based biotech firm Amicus Therapeutics has been forced to terminate its development of its candidate for treating rare skin disease epidermolysis bullosa (EB) after it failed to show any significant efficacy over placebo in Phase 3 trials.

AZ "disappointment" at heart drug failure

AstraZeneca has expressed its disappointment that its heart drug Brilinta (ticagrelor) failed to meet its primary endpoint in a recent trial.

AstraZeneca’s selumetinib fails to meet primary endpoint in lung cancer trial again

AstraZeneca has announced that its MEK 1/2 inhibitor, selumetinib, failed to meet its primary endpoint of progression free survival in patients with KRAS mutation-positive locally-advanced or metastatic non-small cell lung cancer.

The drug candidate failed to meet its primary endpoint in a 2011 Phase II trial in the same indication. In both trials, selutmetinib was used in combination with Sanofi chemotherapy drug Taxotere (docetaxel) as a 2nd line treatment.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches